Monographie - Amphotericin B lipid complex

Ultimo aggiornamento :
08/05/2024

Amphotericin B lipid complex

Struttura chimica

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Abelcet

Argentina, Australia, Austria, Belgio, Brasile, Canada, Danimarca, Finlandia, Francia, Germania, Gran Bretagna, Grecia, Irlanda, Italia, Lussemburgo, Malaysia, Messico, Norvegia, Paesi Bassi, Perù, Portogallo, Romania, Spagna, Stati Uniti d’America, Svezia, Ungheria

Bibliografia : Amphotericin B lipid complex

	Tipo	Pubblicazione
1510	Libro	AHFS Formulary service 2000 Bethesda - 3546 p
2247	Rivista	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Rivista	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3254	Rivista	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratorio	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3644	Laboratorio	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Rivista	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44

Mentions Légales